Page 1 - reflections_newsletter10

REFLECTIONS

Dyslipidaemia
Dyslipidaemia Global Newsletter #10 2025

TABLE OF CONTENTS

KEY ARTICLES Welcome back to the Reflections Dyslipidaemia Global Newsletter,
where an international Scientific Planning Committee summarises
CLINICAL GUIDELINES Dyslipida
and provides expert commentary on the latest clinical and real-
2025 Focused Update of the 2019 ESC/EAS Guidelines world evidence in the field of dyslipidaemia. These articles are
for the management of dyslipidaemias. Mach F, et al. chosen based on their significance to everyday clinical practice.
Atherosclerosis. 2025 August 29;409(120479).
This newsletter highlights updates since the 2019 ESC/EAS
LDL cholesterol management simplified in adults-Lower Guidelines for management of dyslipidaemia, explores new
for longer is better: Guidance from the National Lipid
Association. Jackson EJ, et al. J Clin Lipidol. 2025 Jun 18;000:1-8. guidance on LDL cholesterol management and residual risk, and
delves into the emerging science of triglycerides as both a causal
TREATMENTS AND MODELLING factor and therapeutic target in atherosclerotic cardiovascular
Global impact of fixed-dose combination therapies on disease. It also examines translational advances in lipid-lowering
cardiovascular mortality and events, 2023-2050: A modeling targets, the promise of gene therapy and genome editing for
study. Watkins DA, et al. JACC. 2025 July 14;86(3):149-161. lipoprotein disorders, and new insights into coronary events
The evolving landscape of targets for lipid lowering: From occurring in the absence of traditional risk factors. As with previous
molecular mechanisms to translational implications. newsletters, we invite you to interact through links to short video
Ballantyne CM, et al. Eur Heart J. 2025 Sep 5;ehaf606. doi: https:// commentaries from our SPC, links to videos or podcasts, along
doi.org/10.1093/eurheartj/ehaf606. Online ahead of print. with hyperlinks to full articles for in-depth study and reflection.
Gene therapy and genome editing for lipoprotein disorders.
Gurevitz C, et al. Eur Heart J. 2025 Sep 14;46(35):3420-3433. Prof. Farnier (Chair)
TARGETS AND BIOMARKERS SCIENTIFIC PLANNING COMMITTEE

Great debate: Plasma triglycerides are an important
causal factor and therapeutic target for atherosclerotic
cardiovascular disease. Boren J, et al. Eur Heart J. 2025 Jul Prof. Michel Farnier Prof. Choong Hou Koh
14;46(27):2643-2656. (France) (Singapore)
Occurrence of coronary events in the absence of traditional
risk factors: Understanding residual risk. Arnold N, et al.
Atherosclerosis. 2025 August 9;409 :120475.
Prof. Augusto Lavalle Prof. Ahmed Shawky
Cobo (Egypt)
ADDITIONAL ARTICLES OF INTEREST (Argentina)
CONFERENCE CORNER

Highlighted abstracts of interest from the ESC Prof. Cristina Gavina Prof. Marcin Welnicki
2025 conference (Portugal) (Poland)

CLINICAL GUIDELINES

2025 Focused Update of the 2019 ESC/EAS Guidelines for the management
of dyslipidaemias.

Mach F, et al. Atherosclerosis. 2025 August 29;409(120479).

Since the publication of the 2019 European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) Guidelines for the
management of dyslipidaemias, there have been several randomised controlled trials (RCTs) that might change patient management
ahead of the release of the next full guideline. The 2025 Focused Update of the guidelines, led by Prof. François Mach and
colleagues, responds to the evolving landscape of lipid management by integrating new evidence published up to March 31, 2025.
This update aims to refine treatment strategies, enhance cardiovascular (CV) risk prediction, and incorporate recent therapeutic
advancements.